Speciality: Endocrinology
Description:
A warm welcome to all the medical practitioners in this interesting session on untangling the benefits, cost and access of biosimilar insulin- Glargine.
Insulin is a hormone secreted from pancreas that helps blood sugar to enter the body's cells so it can be used for energy. Insulin also signals the liver to store blood sugar for later use. It is one of the important components that helps in controlling diabetes in patients.
The speakers Dr. Prasun Deb and Dr. Anant Nigam have provided an elaborative knowledge on the needs of biosimilar insulin Glargine with respect to cost and access in the management of diabetes in patients.
Biosimilar insulins are manufactured in living organisms (e.g., yeast and bacteria) to produce large quantities of the product, which limits the ability to manufacture exact replicas of original biological medications. The manufacture and use of biosimilar insulin will be much cost effective and can be used in lower or middle income countries.
Insulin glargine is a product of Biocon, is long-acting, synthetic version of human insulin which works by replacing the normally produced insulin and by helping sugar to move out from the blood into other body tissues where it is used in the form of energy.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.
2.
Relationship-building key to addressing oncologist shortages in rural care
3.
A Texas study found that the majority of pancreatic cancer patients do not receive life-saving surgery.
4.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
5.
Prostate cancer therapies: AI-based image analysis detects early organ damage
1.
Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice
2.
Recent Advances in Paroxysmal Nocturnal Hemoglobinuria Research: Promising Therapies on the Horizon
3.
Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment
4.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
5.
Beyond the Standard: Personalized Cancer Vaccines and the Dawn of a New Era in Pediatric Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation